INTRODUCTION
============

All cells of an organism carry the same genetic information in their nucleic DNA. But the requirements of distinct cell types are different and they also can change upon environmental stimuli. Thus, the expression of genes into proteins has to be adjusted to the particular needs of a cell. This mainly occurs by transcriptional regulation of gene expression, and transcription factors play a pivotal role in this regard. Deregulated transcription factors are involved in the development of many severe diseases, and thus, elucidation of transcription factor regulation can provide valuable information regarding the development and treatment of these diseases.

Transcription factors are proteins that regulate gene expression by binding to the DNA sequences of their target genes and that can be classified according to their DNA-binding domain (DBD). Among the most important ones are homeodomain proteins, zinc-finger proteins, basic helix-loop-helix (bHLH) and leucine zipper (LZ) proteins. Often specific transcription factors contain ligand binding domains as well as one or more transactivating domains (TADs) permitting their ability to act as activators or repressors of gene expression.

With respect to the substantial role of transcription factors in gene expression regulation, it is not surprising that mutant transcription factors as well as deregulated transcription factors can cause tissue damage and thus severe diseases. In cancer, the inappropriate growth of cells is often caused by mutated or malregulated oncogenes or tumor suppressor genes, which, in turn, often encode transcription factors. Prominent examples are the oncogenic transcription factor c-Myc ([@B2]) or the tumor suppressor p53, which is mutated in a variety of human cancers ([@B66]; [@B67]).

The eukaryotic cell features several different mechanisms for the regulation of transcription factor function. One possibility is to tightly control the rate of transcription factor synthesis and/or degradation via the ubiquitin--proteasome system ([@B30]). Posttranslational modifications are also a valuable tool in cellular transcription factor regulation. Beside SUMOylation ([@B121]; [@B44]) or acetylation ([@B9]), protein phosphorylation plays a major role in this respect. In response to diverse extracellular signals, transcription factors can be phosphorylated by specific protein kinases or dephosphorylated by protein phosphatases. Protein phosphorylation is a dynamic process and the phosphorylation state of the transcription factor can affect its function in several ways: by changing the cellular localization, by regulating DNA binding and/or oligomerization of the transcription factor, by modulating interactions with coregulators or by influencing protein stability ([@B126]).

The upstream stimulatory factors (USF1 and USF2) are transcription factors that participate in the regulation of a large number of genes and especially USF2 appears to be crucial for the control of embryonic development, brain function, metabolism, iron homeostasis, fertility and growth whereas USF1 has roles in metabolism, as well as in the tanning and immune response ([@B111]; [@B23]). Furthermore, USFs seems to exhibit a tissue protective and tumor suppressive function in several cancer types ([@B57]; [@B20]; [@B18]). Although the majority of mechanisms regulating USFs are largely unknown, phosphorylation appears to play an important role and the present review aims to summarize the current knowledge about the regulation of USFs by direct phosphorylation and the consequences for USF functions.

THE UPSTREAM STIMULATORY FACTORS
================================

Upstream stimulatory factors were identified in 1985 by their ability to regulate transcription of the adenovirus major late promoter ([@B16]; [@B78]; [@B104]). [@B103] then succeeded in isolating two isoforms of the transcription factor, USF1 (43 kDa) and USF2 (44 kDa), from HeLa cells. Later, the human USF1 gene was located on chromosome 1q22--q23 ([@B109]), whereas the human USF2 gene was found on chromosome 19q13 ([@B49]). Both USF genes consist of 10 protein coding exons ([@B69]). By alternative splicing, two USF2 isoforms, USF2a (44 kDa) and USF2b (38 kDa), can be generated ([@B123]) and have a gene regulatory function. The USF2 splice variant USF2b lacking the information encoded by exon 4 was shown to act as a dominant negative regulator of USF-dependent gene expression. Similar events were described for alternative splicing of exon 4 in USF1 mRNA ([@B47]; [@B42]; [@B98]); again a novel USF1 variant affecting USF-dependent gene regulation was generated ([@B98]).

Although USF1 and USF2 are ubiquitously expressed, their ratio varies in different cell types ([@B112]). Additionally, transcriptional regulation of USFs was discovered. For example, a *Helicobacter pylori* infection caused hypermethylation of the USF2 promoter in mice ([@B14]) and high glucose levels upregulated USF2 gene transcription via a cAMP-response element-binding protein (CREB) response element in the USF2 promoter ([@B108]).

*In vivo* the proteins appear mainly as USF1/USF2 heterodimers; homodimers are quite rare ([@B123]). Experiments with USF knockout-mice revealed that there seems to be an asymmetrical cross-regulation between the two isotypes: USF1^--/--^ mice displayed enhanced USF2 expression, whereas USF2^--/--^ mice had less USF1 protein compared to wt mice ([@B111]).

Upstream stimulatory factors are part of the basic helix-loop-helix leucine zipper (b-HLH-LZ) transcription factor family ([@B47]) which also includes the oncoprotein c-Myc. The characteristic and highly conserved C-terminal b-HLH-LZ domain constitutes the conserved DBD, composed of a basic (b) region, followed by a HLH and a LZ motif. Both, USF1 and USF2, share about 70% identity within the b-HLH-LZ regions whereas the overall identity of the full length proteins is only about 44% ([@B112]). Although the N-terminal regions share only a limited sequence homology, they contain a highly conserved USF-specific region (USR) which is located N-terminal from the basic region. The USR is supposed to play an important role in transcriptional activation ([@B49]; [@B74]; [@B91]). Furthermore, the USR as well as the basic region are important for mediating the nuclear localization of the transcription factor. Dimerization of the transcription factor is dependent on the HLH-LZ motif in the C-terminus of the protein ([@B74]; Figure [1](#F1){ref-type="fig"}).

![**Domain organization and phosphorylation sites within the transcription factors, upstream stimulating factor (USF).** USF1 and USF2 are b-HLH-LZ transcription factors with similar domain organization. The amino acid residues targeted by various kinases are indicated (see text for details). The conserved C-terminus of the USFs consists of a USF-specific region (USR, aa 158--183 in USF1; aa 194--219 in USF2), a basic region, a helix-loop-helix domain (BR-HLH, aa 199--254 in USF1, aa 235--290 in USF2), and a leucine zipper domain (LZ, 271--292 in USF1, 307--328 in USF2); the domain organization is given according to [@B113].](fphar-06-00003-g0001){#F1}

Like the other members of the b-HLH transcription factor family, USFs bind in principle to E-boxes with a CANNTG core sequence in the promoters of their target genes ([@B11]). Whole genome ChIP-chip analyses in human HepG2 hepatoma cells showed that USF1/USF2 bind predominantly to CACGTGAC elements ([@B92]). In addition, USF2 but not USF1 was shown to bind also pyrimidine rich Inr elements in the core promoter of target genes ([@B96]). Due to the differences in the USF1 and USF2 N-termini it was suggested that the two isoforms have the ability to regulate different sets of genes and that they can be regulated in a different manner themselves ([@B74]).

USF1 AND USF2 IN TISSUE PROTECTION AND CANCER
=============================================

Given that USFs were identified as transcriptional regulators of the adenovirus major late promoter, it is not surprising that other viruses like HIV ([@B76]; [@B43]; [@B110]), Varicella-zoster virus ([@B77]) and Epstein--Barr virus ([@B70]) use USFs during their replication cycle. Although these findings may suggest that USFs promote host invasion and tissue damage, it is also well accepted that USFs have rather a tissue protective role.

The role of USFs in tissue protection evolved first from their participation in the transcriptional regulation of the inflammatory genes and genes necessary for the immune response. Recent findings show that USF1 can inhibit inflammatory NF-*κ*B signaling by inducing expression of the gene tumor necrosis factor alpha (TNFα)-induced protein-3 (TNFAPI3, also known as TNFA1P2, OTUD7C, or A20; [@B117]). USF1 also promotes the immune response by stimulating expression of immunoglobulin light chain genes ([@B19]; [@B15]), the complement factor C4 gene ([@B40]), and the major histocompatibility class I complex component β2-microglobulin ([@B45]; [@B52]). Further, USF1 protects the skin from ultraviolet (UV) irradiation by inducing expression of pigmentation genes, and genes encoding factors necessary for nucleotide excision repair (NER; [@B10]). In addition to its proper function as a transcriptional regulator, recent findings unraveled a USF1/p53 crosstalk where in the presence of DNA damage, USF1 stabilizes p53 and induces cell cycle arrest ([@B13]). Moreover, USF2 was supposed to suppress cyclin-dependent kinase 4 (Cdk4) expression. Thus, the finding that USFs contribute to cell cycle regulation indicates their importance for cell protection, growth, and developmental processes.

Examination of USF-deficient mice illustrated that a minimum level of USF activity is required for embryonic development since USF1^--/--^/USF2^--/--^ mice die during embryogenesis. Both USFs seem to play a role in brain development because USF1^--/--^ as well as USF2^--/--^ mice were prone to spontaneous epileptic seizures. While USF1^--/--^ mice had no other obvious problems, more than half of the USF2^--/--^ pups died within two days after birth. USF2^--/--^ mice were about 20--40% smaller than their heterozygous siblings, male USF2^--/--^ had a drastically reduced lifespan and both male and female USF2^--/--^ mice had reduced fertility ([@B119], [@B118]; [@B111]; [@B50]).

A recent study with USF2^--/--^ mice revealed that male USF2^--/--^ mice display dysregulated prostate growth and marked prostate hyperplasia already at a young age ([@B20]). This might be one of the reasons for the early death of male USF2^--/--^ mice. In line with this hypothesis, the authors have shown that the USF2 protein level of several prostate cancer cell lines is markedly decreased and that ectopic expression of USF2 in PC-3 prostate cancer cells inhibits their tumorigenicity. These data suggest that USF2 might have a tumor-suppressive function in prostate carcinogenesis ([@B20]).

That the action of USF2 as suppressor may be of special importance for prostate cancer was first highlighted by a study investigating hormone refractory prostate cancer samples. Half of the hormone refractory prostate cancer samples displayed a loss of chromosome 19q ter-q13.1 ([@B82]) which includes the region with the *Usf2* gene ([@B114]). A reintroduction of an intact human chromosome 19 into a tumorigenic prostate cell line reduced tumorigenicity in athymic nude mice ([@B8]). In addition, USF2 has recently been found to be part of the prostatic factor complex as an androgen receptor cofactor ([@B61]) and it was found to be downregulated in human prostate cancer specimens ([@B20]). Recent investigations with a mouse *in vivo* xenograft model further substantiated the inhibitory role of USF2 since overexpression of USF2 in prostate cancer cells inhibited the tumorigenicity of these cells ([@B20]).

There are also other studies suggesting a role of USF2 in the development of cancer. In breast cancer cell lines, USF1 and USF2 were expressed, but a significant loss of transcriptional activity of both proteins was observed in approximately 50% of the transformed breast cell lines indicating that loss of USF function favors proliferation ([@B57]). Furthermore, it was observed that USFs may have a potent growth-inhibitory effect and can antagonize the transforming function of the oncoproteins c-Myc and Ras in rat embryonic fibroblasts ([@B73]; [@B22]). Indeed, transfection of either USF1 or USF2 inhibited cellular transformation induced by c-Myc or activated Ras. In addition, USF2 also inhibited transformation in rat embryonic fibroblasts (REFs) induced by the adenovirus oncoprotein E1A, while USF1 did not, which highlights the broader inhibitory function of USF2 ([@B73]).

In line, many cancer cells including the prostate cancer cell line PC-3 ([@B57]; [@B91]) displayed a loss of USF2 transcriptional activity while it was active in non-tumorigenic cells.

Further, not only the oncogenes c-Myc and Ras, whose function could be counteracted by USF2 have been implicated in prostate cancer, but also tumor suppressor genes. Among the about 2500 genes which are supposed to be regulated by USFs ([@B92]) are those encoding the tumor suppressors adenomatous polyposis coli (APC), breast cancer 2 (BRAC2) or p53 ([@B93]; [@B27]; [@B58]; [@B130]). In addition, a number of genes important for cellular growth and metabolism like fatty acid synthetase (FAS), pyruvate carboxylase, pyruvate kinase, heme oxygenase (HO-1), plasminogen activator inhibitor-1 (PAI-1) or Cdk4 contain E-boxes that bind USF in their promoters ([@B93]; [@B58]; [@B130]; [@B131]). Furthermore, the tumor-suppressor function of USFs was linked with their ability to repress the human telomerase reverse transcriptase (hTERT) expression in oral cancer cells; hTERT promotes immortalization and malignant transformation of cancer cells by stabilizing telomeric ends of chromosomes ([@B18]).

Contrary to the studies suggesting a tumor suppressor role for USF2 in carcinogenesis, there is one study indicating that USF2 has a pro-proliferative function in lung cancer cells ([@B83]).

INVOLVEMENT OF CO-FACTORS IN THE REGULATION OF USF ACTIVITY
===========================================================

There are some studies suggesting that the presence or availability of coactivators seems to play an important role in USFs activity. Indeed, both USF1 and USF2 were reported to associate with Fra1, a member of the b-Zip protein family, to promote transcription, demonstrating that cross-talk occurs between distant members of the protein family ([@B87]; [@B100]). In addition, the bHLH transcription factor Cha could also constitute an important interactor, at least for USF1 where formation of the USF1/Cha heterodimer negatively affects USF-dependent transcription ([@B95]). Although no proof has been obtained so far whether posttranslational modification events or just specific occurrence of these interactors regulate USF function, they may contribute to different cellular localization of USFs, in particular USF2. Since nuclear translocation of USF2 seems to be a tool for its regulation ([@B39]; [@B53]), the involvement of interacting factors in this process was proposed in experiments showing that USF2 was expressed and properly localized in the nucleus of Saos-2 cells, although USF2 was completely inactive in these cells ([@B91]). Another study suggested the involvement of cofactors in the regulation of USF2 since it was polyubiquitinated and subsequently degraded by the proteasome in response to hypoxia ([@B59]). In line with this, recent studies indicated that USF2 but not USF1 was required for hypoxia-dependent expression of genes regulated by the hypoxia-inducible transcription factor HIF2α. Thereby, USF2 binds to HIF2 target gene promoters, interacts with HIF2α, and recruits coactivators like CREB-binding protein (CBP) and p300 ([@B86]).

Moreover, USF2 in conjunction with the transcription factors YY1 and CCAAT/enhancer binding protein-β (C/EBPβ) affect expression of the cystic fibrosis transmembrane conductance regulator gene (CFTR) with YY1 being a repressor and USF2 being an activator. C/EBPβ appears to act as a switch; its phosphorylation favors the interaction between USF2 and YY1 thus blocking the inhibitory activity of the latter, in favor of C/EBPβ transactivation ([@B122]). Overall, this indicates that phosphorylation evokes an additional layer of complexity to the mechanisms influencing gene expression.

PHOSPHORYLATION-DEPENDENT REGULATION OF USFs
============================================

So far, not much is known about the mechanisms contributing to the regulation of USFs in cancer and in general. Although phosphorylation appears to be a powerful and fast acting mechanism by which USFs function can be modulated, phosphorylation of USF proteins has not yet been investigated intensively and the number of studies showing direct phosphorylation of USF proteins by a kinase at certain residues is limited.

INDIRECT EVIDENCE OF PHOSPHORYLATION-DEPENDENT REGULATION OF USFs
-----------------------------------------------------------------

The first indirect evidence suggesting that USF1 might be a phosphoprotein came from the finding where phosphatase treatment of a purified USF1-like factor significantly reduced its DNA binding activity ([@B76]). Additionally, sphingosylphosphocholine (SPC) treatment of Swiss 3T3 fibroblasts resulted in enhanced USF1 DNA binding ([@B12]). Due to the fact that SPC can activate host kinases ([@B107]) it was suggested that SPC induced phosphorylation of USF1 ([@B12]) although this has not yet been shown. In addition, it has been reported that non-phosphorylated USF1 binds to the apolipoprotein A5 E-box and stimulates its transcription in HepG2 cells; insulin treatment reduced this, most likely via phosphorylation through the phosphatidylinositol-3-kinase (PI3K) pathway ([@B81]). However, the localization and the relevance of the amino acid residues responsible for that effect were not shown, yet.

DIRECT EVIDENCE OF PHOSPHORYLATION-DEPENDENT REGULATION OF USFs
---------------------------------------------------------------

More direct evidence for USF1 phosphorylation came from a study showing that USF1 is a phosphoprotein *in vivo*, and that the phosphorylated form of USF1 bound preferentially to an E-Box in the C4 complement gene promoter ([@B40]).

### Involvement of MAPK signaling in USF regulation

Mitogen-activated protein kinases (MAPKs) are a large family of serine/threonine kinases converting various extracellular signals, among them growth factors, mitogens or inflammatory cytokines, into intracellular responses through serial phosphorylation cascades, thus regulating cellular processes like proliferation, differentiation, development, stress responses, and apoptosis. Conventional MAPKs include extracellular signal-regulated kinase (ERK), ERK1 and ERK2 (p44/p42), c-Jun NH2-terminal kinase (JNK1/2/3), p38 MAPK (p38α/β/γ/δ) and ERK5. In addition, some atypical MAPKs such as ERK3/ERK4, NLK (nemo-like kinase), and ERK7/ERK8 have been identified but less is known about their regulation, substrate specificity and physiological functions (for review, see [@B25]). From the kinases mentioned, only ERK1/2 and p38α have been described to phosphorylate USFs.

***ERK1/2 and USFs.*** Several studies suggested a role for ERK1/2 in the phosphorylation of USFs. In HepG2 cells ERK-mediated phosphorylation of USF1 could be detected following hepatocyte growth factor (HGF) treatment of the cells ([@B56]). Furthermore, ERK1/2-dependent activation of USFs was shown following *Helicobacter pylori* infection, though no direct phosphorylation was shown in these studies ([@B60]). Further, it was found that USFs are downstream targets of the MAPK kinase (MEK)/ERK pathway in trigeminal ganglion neurons ([@B85]). In all cases of the above mentioned studies, the authors claim that ERK1/2-dependent USF phosphorylation induces the transcriptional activity of USF ([@B85]; [@B60]; [@B56]).

More clear evidence for the importance of USF regulation by phosphorylation and their implication in cancer came from various studies investigating the expression of PAI-1. In many cancer types elevated PAI-1 levels can be detected and nowadays PAI-1 became a high evidence marker of a poor prognosis in breast cancer. Although the exact mechanisms by which PAI-1 influences tumor growth and dissemination remain partially controversial, it is evident that PAI-1 exerts its effects not only on fibrinolysis but also on cell attachment, migration and angiogenesis ([@B6]; [@B33]; [@B28]; [@B32]).

Plasminogen activator inhibitor-1 gene expression is tightly regulated and can be induced by a variety of hormones (insulin, glucagon, glucocorticoids, angiotensin II), growth factors (insulin-like growth factor, IGF-I; transforming growth factor-β, TGF-β), cytokines (interleukin-1, IL-1), TNFα, metabolic signals (glucose) and environmental signals (hypoxia; [@B32]).

In this context USFs seem to be quite important in mediating the response of several signals to the PAI-1 promoter. USF1 was shown to stimulate PAI-1 expression when being induced by serum ([@B125]) and by wounding ([@B89]). Thereby, phosphorylation of USF1 seemed to be required for DNA binding ([@B21]; [@B89]). USF2 repressed PAI-1 expression in primary rat hepatocytes ([@B101]); likewise USF2 mediated suppression of PAI-1 expression in response to the polyphenol quercetin in human endothelial cells ([@B84]); however, it induced PAI-1 expression in human and in rat hepatoma cell lines, indicating that the effect of USF2 on PAI-1 expression is cell-type specific ([@B31]). In this context it was shown that binding of USFs is important for HGF-mediated induction of PAI-1 gene expression ([@B56]). Thereby, USF1 was phosphorylated through the MAPK pathway which appears to be also important in mediating PAI-1 transcription in response to TGF-β ([@B94]; [@B3]). In human epidermal keratinocytes USF1 and USF2 occupy the human PAI promoter in a dynamical manner as a function of growth state. While USF1 binds in quiescent cells and represses PAI-1 expression, USF2 stimulates expression after serum-stimulated binding to the human PAI promoter ([@B90]). In this context MAPK-mediated phosphorylation of USF1 at Thr153 is required for suppression of PAI-1 expression ([@B90]). Recent studies suggested that TGF-β-induced PAI-1 expression is dependent on epidermal growth factor receptor (EGFR)-mediated stimulation of the MEK/ERK pathway and that USF1 is phosphorylated by this signaling cascade ([@B64]; [@B99]).

Overall, these studies indicate that USF1 can be phosphorylated via the ERK1/2 pathway while less is known about the role of ERK1/2 on USF2. In addition, cell-type specific components need to be considered and to be discovered to fully understand the role of phosphoUSF1 in PAI-1 expression and cancer.

***P38 and USFs.*** The p38 MAPKs were identified as modulators of TNF signaling ([@B97]) but meanwhile p38 MAPKs were found to be activated by many other stimuli including oxidative and chemical stress, osmotic and heat shock as well as hormones. There are at least four p38 kinases named α, β, γ, and δ, from which the p38α enzyme is the best characterized ([@B97]). A study describing that USF1 is involved in the UV stress response in COS7 and B16 melanoma cells was the first showing that not JNK but the stress-responsive p38α acts as an USF1-phosphorylating kinase. The p38α-mediated phosphorylation occurred in the N-terminal part of USF1 at Thr153 and induced transcription of the tyrosinase gene ([@B41]). The tyrosinase is the rate-controlling enzyme for the production of melanin and thus is necessary for pigmentation and the tanning response. Moreover, USF1 seems to be also critical for the transcriptional induction of other genes like pro-opiomelanocortin, and melanocortin 1 receptor which failed to be activated following UV stimulation in USF1^--/--^ melanocytes ([@B24]).

Since UV light is not only known to induce a tanning but also a DNA damage response ([@B130]; [@B34]), it is possible that UV irradiation promotes the interaction of USF transcription factors with genes involved in NER of DNA. Indeed, recent findings indicate that the proximal promoters of HR23A (homologues of the yeast RAD23) and CSA (excision repair cross-complementation group 8) contained E-boxes and were regulated by USFs ([@B10]). Overall, these findings support the view that phosphorylation of USF-1 by p38 can contribute to the protection of skin against UV light-induced DNA damage.

In this regard the phosphorylation of USF1 by p38α may be important in tissue protection against skin cancer. Together, these findings again underline the potential tumor suppressive aspects of USFs.

### Involvement of other kinases

***Cdk2 and USFs.*** The cell cycle is regulated by the interplay of a catalytic Cdk and its regulatory cyclin. The Cdk2 is an important regulator within this process. It is critical for G1-S transition within the cell cycle, the initiation of DNA synthesis, but also for modulating G2 progression. It appears to be crucial for cancerogenesis since it is orchestrating a fine balance between cellular proliferation, cell death, and DNA repair ([@B102]). In this respect one study indicated that USF1 can be phosphorylated by Cdk2 within a region encompassing the amino acids from 143 to 197; this phosphorylation event increased the DNA-binding activity of the transcription factor ([@B21]). These data may be of importance in the context of cancer cell proliferation where this type of regulation may counterbalance the effects of c-Myc. Interestingly, c-Myc can also be phosphorylated by Cdk2 ([@B54],[@B55]); in contrast to USF1, Cdk2 phosphorylated c-Myc displays reduced DNA-binding activity. In this respect phospho-USF1 may outcompete c-Myc and coordinate a cellular response where USF1 would be anti-proliferative.

***Protein kinase C (PKC) and USFs.*** PKC is a superfamily of serine/threonine kinases consisting of about 10 to 12 isoforms divided in three subfamilies based on their second messenger requirements (for review, see [@B4]; [@B46]). With respect to USFs, it was reported that PKC can phosphorylate rat USF1 *in vitro* and *in vivo* in neonatal rat ventricular myocytes ([@B132]). In that setting PKC-mediated phosphorylation of USF1 increased the binding activity to the cardiac α-myosin heavy chain promoter ([@B132]). In the study of [@B132] a rat brain extract containing a mixture of PKC isoforms α, β, and γ was used. Since distinct PKC isoforms differ in their substrate specificity ([@B17]) it is possible that the various PKC isoforms may confer different effects. Although no data for USF2 are available, these data imply that USFs respond to PKC signaling. However, it remains open to what extend the different isoforms and cell-type specific factors contribute to their function. Hence, further studies would be necessary to better understand the role of PKCs and USF phosphorylation in the context of cancer.

***DNA-dependent protein kinase (DNA-PK) and USFs.*** The DNA-PK is a heterotrimer consisting of the DNA-dependent protein kinase catalytic subunit (PRKDC) and a dimer composed of the Ku p70 and Ku p86 (XRCC6-XRCC5) proteins. It acts as a serine/threonine-protein kinase that usually responds as a molecular sensor for DNA damage. It is involved in the non-homologous end joining (NHEJ) double-strand break (DSB) DNA repair. There, it usually associates with the DNA-bound Ku heterodimer, but it can also bind to and be activated by free DNA. Apart from phosphorylating histone H2A it was found to modulate transcription factors like c-Jun, p53, or c-Myc and contributes to the determination of the circadian period length by affecting Cry1 phosphorylation ([@B29]; [@B26]).

Moreover, a recent study implicated a function of DNA-PK in insulin signaling. This study proposed a model where feeding or insulin activates DNA-PK by dephosphorylation caused by the action of protein phosphatase 1 (PP1). As a consequence DNA-PK phosphorylates USF1 at Ser262 in the b-HLH-LZ domain. Phosphorylation of USF1 allows p300 associated factor (P/CAF) recruitment and subsequent acetylation of USF1 at Lys237. This acetylation event then enhanced the transcriptional activity of USF1 with respect to the FAS promoter ([@B128]).

Recently it has become obvious that beside its metabolic functions in lipogenesis, FAS also seems to play an important role in carcinogenesis. It was observed that FAS expression was elevated in breast, prostate, colon, ovary, endometrium, and thyroid tumor tissues compared to normal tissue. FAS expression thereby seems to confer a growth and/or survival advantage and is associated with a poor prognosis ([@B62], [@B63]). The findings that insulin via DNA-PK can contribute to enhanced FAS expression would argue against a tumor suppressive role of USF1; however, in contrast to normal tissue where FAS is mainly regulated by diet, in cancer cells FAS seems to be regulated also through the MAPK and the PI3K pathways with additional intracellular players ([@B120]; [@B133]). Thus, other factors than USFs may have a more dominant role for the regulation of FAS expression in cancer cells.

***Protein kinase A (PKA) and USFs.*** PKA, a cAMP-dependent protein kinase, is an ubiquitous serine/threonine kinase involved in a wide range of cellular processes such as transcription, metabolism, cell cycle, and apoptosis ([@B7]; [@B115]). The intracellular cAMP level regulates cellular responses by altering the activity of PKA. PKA was found to be involved in USF regulation in the bovine system. In a study investigating the effect of forskolin and PKA on the bovine prostaglandin G/H-2 synthase promoter, it was found that overexpression of PKA enhanced USF DNA binding in bovine granulosa cells. While bovine USF1 contains two putative PKA sites, bovine USF2 contains three PKA phosphorylation sites. Interestingly, only mutation of S275 in bovine USF1 reduced but did not abolish its transactivation capacity whereas mutation of the second putative PKA site S262 had no effect in the context of the prostaglandin G/H-2 promoter ([@B105]). By contrast, when single mutations were introduced at the putative PKA phosphorylation sites S259, S269, and S275 in USF2, this reduced but did not abolish its transactivation capacity ([@B105]).

The cAMP-mediated pathway and a correct functioning PKA cascade was found to be involved in the regulation of the cell cycle via cyclin D. A defect in this cascade would again link cAMP, PKA, and USFs with the development of cancer. However, the link appears to be controversial. Although a reduction in cAMP has an anti-proliferative effect on colorectal cancer cells ([@B71]), an increase in the PKA type I isozyme induces a non-tumorigenic phenotype in lung cancer cells ([@B88]). To what extend USFs are involved in this response has not yet been unraveled and further studies would be needed to gain more insight into the connection of PKA and USF regulation during cancerogenesis.

***Glycogen synthase kinase-3 (GSK-3) and USFs.*** GSK3 is a serine/threonine kinase that was first identified as a negative regulator of glycogen synthesis; inhibition is achieved through phosphorylation of glycogen synthase ([@B36]; [@B129]). Since its initial discovery, GSK3 was found to be a key player in several signal transduction pathways, such as the PI3K/Akt pathway, the Wnt/β-catenin pathway or the Hedgehog signaling pathway. Due to these multiple involvements, dysregulation of GSK3 has been implicated in the pathogenesis of human diseases, including type-2 diabetes, bipolar disorders, inflammation, Alzheimer's disease, and cancer (reviewed by [@B38]; [@B48]). Two isoforms, GSK3α (51 kDa) and GSK3β (47 kDa), have been identified in mammals. Despite their homology in the catalytic domain (98%), they significantly differ in their N- and C-terminal parts and do not have entirely overlapping roles in metabolism (reviewed in [@B35]; [@B37]).

While GSK3β promoted cancer development and growth in some types of cancer, it had a tumor suppressor function in other types since a decrease in GSK3β function or expression was observed in these tumors ([@B72]). In line with the latter findings and in the context of phosphorylation-dependent regulation of USFs, a recently published article reports GSK3β-induced phosphorylation of USF1 following inhibition of the PI3K pathway ([@B116]). By means of mass spectrometry analysis of GSK3β-phosphorylated human recombinant USF1 protein, the authors identified Thr153 and Ser186 as the phosphorylated amino acids. While phosphorylation of Thr153 was important for the transcriptional activation of genes promoting apoptosis and cell cycle arrest, phosphorylation of Ser186 had no effect ([@B116]).

In addition, GSK3β acts also as an USF2-phosphorylating kinase. The phosphorylation sites within USF2 could be mapped to serine 155 and threonine 230. *In silico* analyses of the 3-dimensional structure revealed that phosphorylation of USF2 by GSK3β converts it to a more open conformation which may influence transactivity, DNA binding and target gene expression. Indeed, experiments with GSK3β-deficient cells revealed that USF2 transactivity, DNA binding and target gene expression were reduced upon lack of GSK3β. Further, experiments with USF2 variants mimicking GSK3β phosphorylated USF2 in GSK3β-deficient cells showed that phosphorylation of USF2 by GSK3β did not affect cell proliferation but increased cell migration ([@B51]). Together, these studies indicate that GSK3β is an important modulator of USF function; however, the exact function of both, GSK3β and USF2 in cancerogenesis appears to be variable and may depend on the cellular context. Some studies support the idea of GSK3β and USF2 being tumor suppressive ([@B73]; [@B1]), other studies show a cancer promoting effect ([@B83]; [@B65]). Although no study has yet correlated the activity of GSK3β with the activity of USF2 in a certain tumor setting, the findings of the latter study would favor the tumor promoting aspects of GSK3β and USF2 since GSK3β activated USF2 enhanced cell migration which may be important in terms of tumor cell metastasis. However, different growth conditions, the cellular or tissue-specific context may influence the activity of USF2.

In summary, more studies on the regulation of the transcription factor USF2 are necessary to understand the mechanisms by which it affects the development of different types of cancer.

***CK2 and USFs.*** Protein kinase CK2 (formerly known as casein kinase II) is considered to act as messenger-independent protein serine/threonine kinase. CK2 is a tetrameric enzyme consisting of two catalytic α and α′ subunits and two non-catalytic β-subunits. Interestingly, the majority of CK2 targets are proteins involved in signaling, protein synthesis and transcriptional regulation ([@B79]). Over the last 10 years a number of transcription factors have been detected which are phosphorylated by CK2; phosphorylation enhances transcriptional activity of activating transcription factor 4 (ATF4; [@B5]), HIF1α ([@B80]), upstream binding factor (UBF; [@B68]) and FoxM1c ([@B127]) and reduces transcriptional activity of PDX-1 ([@B124]) and Chop ([@B106]) just to mention a few. A recent report combining *in silico*, *in vitro* and *in vivo* assays added USF1 but not USF2 to that list. Further, by using USF1 deletion mutants and point mutants that study identified threonine 100 as the major phosphorylation site for CK2. In addition, inhibition of CK2 with a specific inhibitor enhanced binding of USF1 to USF2, i.e., heterodimerization. Furthermore, transactivation studies showed that inhibition of CK2-dependent phosphorylation of USF1 stimulated transcription from the pancreatic glucokinase promoter as well as the FAS promoter but not from the HO-1 promoter ([@B75]). Thus, this study shows that phosphorylation of USF1 by CK2 modulates two functionally important properties of USF1, namely heterodimerization and transactivation.

CONCLUSION
==========

Transcription factors are critical components within signal transduction pathways and via regulating the expression of various genes they are involved in various aspects of cellular functions including regulation of cell growth and cell death. Therefore, disturbances within the proper function of transcription factors may be related to tumorigenesis and cancer. Phosphorylation events are fundamental processes achieved through the activity of various protein kinases which allow immediate control of protein activity including transcription factor function. Thus, the knowledge of the signaling pathways and the involved kinases are of immediate importance to understand the regulation and proper function of transcription factors. The transcription factors USF1 and USF2 have been shown to be subject of phosphorylation by different kinases; though most of the studies refer to USF1. In addition to their involvement in embryonic development, brain function, metabolism, iron homeostasis, fertility, pigmentation, and the immune response it became also evident that USFs affect tumorigenesis. Since kinase inhibitors became a feasible therapeutic approach in anti-tumor therapy within the last decade, they may be considered also to be of use in terms of the role of USFs in tumorigenesis and cancer. However, a concise view about the impact of USF's phosphorylation during tumorigenesis has not been reached. The different phosphorylation events need to be considered in a more specific cellular context and in conjunction with USF interacting proteins. This may be of special importance since the phosphorylation events together with cell-specific USF interacting partner molecules may then render USFs either into a tumor suppressor or tumor promoter. Thus, more studies in particular considering interacting partners and cell-type specific effectors are necessary to further define the mode by which USFs affect tissue injury, inflammation, and tumorigenesis.
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